NCT06620055 Development of an Artificial Intelligence Model for Optimising Therapy in Gliomas Gliomas
| NCT ID | NCT06620055 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Centro di Riferimento Oncologico - Aviano |
| Condition | Glioma |
| Study Type | OBSERVATIONAL |
| Enrollment | 164 participants |
| Start Date | 2023-11-16 |
| Primary Completion | 2028-11-16 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 164 participants in total. It began in 2023-11-16 with a primary completion date of 2028-11-16.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Artificial intelligence (AI) undoubtedly represents the main tool currently available in the definition of complex algorithms and its use in the medical field is becoming increasingly strategic.As reported in the literature, it is increasingly difficult to find new therapeutic strategies for neoplasms, especially neurological ones. Molecular characterisation is therefore increasingly essential, as is the use of new predictive methods. With this in mind, the aim of this study is to assess, by means of AI algorithms applied to genomic data, in what percentage molecular alterations are susceptible to potential drug therapies, compared to the literature data that does not consider AI algorithms for this purpose.
Eligibility Criteria
Inclusion Criteria: 1. Patients with a histopathological diagnosis of glioma for whom it is possible to have cryopreserved or fixed in formalin and embedded in paraffin biological material. Specimens may result from incisional biopsy and/or surgical resection and/or blood. Whole blood is taken for germinal analysis; 2. Age \>=18 years; 3. Patients must understand and provide written informed consent; 4. Life expectancy \>3 months; 5. Presence of biological material from resection and blood considered sufficient by quality and quantity to proceed to molecular characterisation in the opinion of the Investigator Principal Investigator; 6. Presence of available and accessible clinical and histopathological data. Exclusion Criteria: 1. Refusal of informed consent; 2. Uncooperative patients; 3. Presence of other neoplastic diseases in the last 5 years; 4. Pregnant and/or breastfeeding women
Contact & Investigator
Giuseppe Toffoli
PRINCIPAL INVESTIGATOR
Centro di Riferimento Oncologico di Aviano (CRO) - IRCCS
Frequently Asked Questions
Who can join the NCT06620055 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Glioma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06620055 currently recruiting?
Yes, NCT06620055 is actively recruiting participants. Contact the research team at gtoffoli@cro.it for enrollment information.
Where is the NCT06620055 trial being conducted?
This trial is being conducted at Aviano, Italy, Padova, Italy, Udine, Italy.
Who is sponsoring the NCT06620055 clinical trial?
NCT06620055 is sponsored by Centro di Riferimento Oncologico - Aviano. The principal investigator is Giuseppe Toffoli at Centro di Riferimento Oncologico di Aviano (CRO) - IRCCS. The trial plans to enroll 164 participants.